DEF 14A: Turnstone Biologics Corp. Announces Annual Meeting of Stockholders to be Held Virtually on June 3, 2024

Turnstone Biologics Corp. will hold its annual meeting of stockholders virtually on June 3, 2024, to elect directors and ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm.

Summary

• Turnstone Biologics Corp. is holding its Annual Meeting of Stockholders on June 3, 2024, at 1:30 p.m. Pacific Time, as a virtual meeting via live audio webcast.
• Stockholders of record as of April 12, 2024, are eligible to vote.
• The meeting will address the election of three Class I directors to serve until the 2027 Annual Meeting and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting 'For' all director nominees and 'For' the ratification of Ernst & Young LLP.
• Stockholders can vote online during the meeting or in advance via telephone or internet.
• The company's Board of Directors has seven members.
• The Board has determined that all directors, except Drs. Farah and Burgess, are independent.
• The Board of Directors met nine times during the last fiscal year.
• The Audit Committee is composed of three directors: Mr. Waddill, Dr. Gould and Mr. Gupta, with Mr. Waddill serving as chair.
• The Compensation Committee is composed of three directors: Mr. Gupta, Dr. Davis and Mr. Waddill, with Mr. Gupta serving as chair of the compensation committee.
• The Nominating and Corporate Governance Committee is composed of three directors: Drs. Davis, Gould and Rajangam.
• The company has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.
• The company has adopted a written Related Person Transactions Policy that sets forth the company’s policies and procedures regarding the identification, review, consideration and approval or ratification of related persons transactions.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions. The sentiment is slightly positive due to the routine nature of the meeting and the board's recommendations.

Positives

• The virtual meeting format provides expanded access, improves communication, and enables increased stockholder attendance and participation.
• The Board of Directors is composed of a majority of independent directors.
• The company has a Code of Business Conduct and Ethics and Corporate Governance Guidelines in place.
• The Audit Committee has a financial expert, William Waddill, meeting SEC regulations and Nasdaq listing standards.
• The company has a written Related Person Transactions Policy that sets forth the company’s policies and procedures regarding the identification, review, consideration and approval or ratification of related persons transactions.

Negatives

• Two directors, Drs. Farah and Burgess, are not considered independent due to their executive roles within the company.
• The Nominating and Corporate Governance Committee did not meet during the fiscal year 2023.

Risks

• Failure to ratify the selection of Ernst & Young LLP as the independent auditor could require the Audit Committee to reconsider its selection.
• Cybersecurity threats are a risk, and the Audit Committee oversees cybersecurity risk management processes.
• Related person transactions, while subject to review and approval, could present potential conflicts of interest.

Future Outlook

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting.

Management Comments

• The Company believes that the lead independent director can help ensure the effective independent functioning of the Board of Directors in its oversight responsibilities.
• The Company believes that the lead independent director is better positioned to build a consensus among directors and to serve as a conduit between the other independent directors, for example, by facilitating the inclusion on meeting agendas of matters of concern to the independent directors.

Industry Context

This announcement is a standard part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions regarding the company's direction and oversight.

Comparison to Industry Standards

• The virtual meeting format is increasingly common among public companies to enhance accessibility and reduce costs, aligning with trends seen at companies like Fulcrum Therapeutics (Nasdaq: FULC) and Arrowhead Pharmaceuticals.
• The composition of the board, with a mix of financial experts, biotech veterans, and venture capital representatives, is typical for a company in the biotechnology sector, similar to the boards of Synlogic, Inc. (Nasdaq: SYBX) and Senti Biosciences (NASDAQ: SNTI).
• The compensation structure for non-employee directors, including cash retainers and equity grants, is consistent with industry practices observed at companies like Protagonist Therapeutics, Inc. and Annexon, Inc.

Management Changes

Related Party Transactions

• In July 2023, certain stockholders owning more than 5% of the company's stock purchased shares in the IPO, including OrbiMed Capital GP VI, LLC and Versant Ventures Management, LLC.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, influencing the company's governance and financial oversight.
• Employees are indirectly affected by the election of directors and the ratification of the auditor, as these decisions impact the company's overall stability and direction.

Next Steps

• Stockholders are encouraged to vote by proxy in advance of the Annual Meeting.
• Attend the virtual Annual Meeting on June 3, 2024, to participate in the live webcast, submit questions, and vote.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Ernst & Young LLP, Audit Committee, Executive Compensation, Corporate Governance, Stockholders, Independent Directors